Head-to-head comparison of [18F]-fluorodeoxyglucose and [18F]-fluorocholine positron emission tomography/computed tomography in three patients with rare gestational trophoblastic neoplasms: A case series

Abstract We report the efficacy of dual positron emission tomography/computed tomography (PET/CT) imaging with [ 18 F]-2'-fluoro-2'-deoxy-D-glucose ([ 18 F]-FDG) and [ 18 F]-fluorocholine ([ 18 F]-FCH) in patients with gestational trophoblastic neoplasia (GTN) for primary diagnosis and sta...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:World journal of nuclear medicine 2020-01, Vol.19 (1), p.72-77
Hauptverfasser: Thientunyakit, Tanyaluck, Thongpraparn, Thonnapong, Siriprapa, Tossaporn, Gelovani, Juri G.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Abstract We report the efficacy of dual positron emission tomography/computed tomography (PET/CT) imaging with [ 18 F]-2'-fluoro-2'-deoxy-D-glucose ([ 18 F]-FDG) and [ 18 F]-fluorocholine ([ 18 F]-FCH) in patients with gestational trophoblastic neoplasia (GTN) for primary diagnosis and staging of this rare pregnancy-related disorder. Whole-body PET/CT with [ 18 F]-FDG and [ 18 F]-FCH was performed in three patients with GTN in 2 consecutive days. Each detectable lesion was characterized by visual and quantitative analyses. As compared to CT alone, PET/CT with [ 18 F]-FDG and [ 18 F]-FCH PET/CT revealed more hypermetabolic metastatic lesions in the body, but not in the brain. The standard uptake value of [ 18 F]-FDG was generally higher than [ 18 F]-FCH in all detectable tumor lesions. In conclusion, both [ 18 F]-FDG and [ 18 F]-FCH PET/CT can be used for diagnosis and staging for GTN, based on their sensitivity for small extracerebral metastatic lesions. Additional studies are warranted to determine whether the PET/CT imaging with [ 18 F]-FDG and [ 18 F]-FCH can serve as a biomarker of GTN aggressiveness, for prediction of treatment response.
ISSN:1450-1147
1607-3312
DOI:10.4103/wjnm.WJNM_91_18